Systemic Metabolic Contribution From Continuous Renal Replacement Therapy (CRRT)

Acute Kidney Injury Clinical Trial

Official title:

Quantification of Systemic Metabolic Contribution From Continuous Renal Replacement Therapy (CRRT) Utilizing Regional Citrate Anticoagulation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02998346
• Other study ID #: 13-009155
• Status: Completed
• Phase: N/A
• First received: December 16, 2016
• Last updated: January 29, 2018
• Start date: April 2014
• Est. completion date: June 28, 2017

Study information

• Verified date: January 2018
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this observational study is to measure the number of calories delivered from fluids used in continuous renal replacement therapy (CRRT). We are doing this research study because the fluids used in this treatment may deliver an important number of calories. In the future this could help better estimate how much nutrition patients in the Critical Care Unit should get every day from other sources like tube feeding or nutrition through a person's veins.

Description:

The goal of this study is to quantify the specific metabolic contribution of standard continuous renal replacement protocols (including citrate anticoagulation) in the intensive care unit patient population at Mayo Clinic in Rochester, Minnesota utilizing a prospective, observational study. This data will allow practitioners to better tailor caloric provision with nutrition support programs, minimizing the risk of overfeeding in this complex critical care patient population.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: June 28, 2017
• Est. primary completion date: June 28, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age greater than or equal to 18 years

• Patients in an intensive care unit anticipated to receive greater than or equal to 24 hours of continuous venovenous hemofiltration.

• Receiving regional citrate anticoagulation with ACD-A solution.

Exclusion Criteria:

• Vulnerable adults

• Pregnant

• BMI > 40

• Patient on extracorporeal membrane oxygenation therapy

• Reversal of port connections on the dialysis catheter and dialysis circuit lines

Related Conditions & MeSH terms

• Acute Kidney Injury

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Mayo Clinic

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Quantify net glucose uptake from citrate and dextrose-containing fluids from continuous venovenous hemofiltration		Two days
Primary	Quantify net citrate uptake from citrate and dextrose-containing fluids from continuous venovenous hemofiltration		Two days